Membrane-bound or soluble, mesenchymal or myeloid: which RANKL drives osteoclastogenesis?

Abstract

Receptor activator of nuclear factor-κB ligand (RANKL) is indispensable for osteoclast differentiation, activation, and bone resorption. While the relative contributions of membrane-bound RANKL (mRANKL) and soluble RANKL were historically debated, evidence from the past decade increasingly establishes mRANKL as the primary driver of osteoclastogenesis. However, a systematic literature synthesis integrating these diverse cellular sources and structural modalities remains lacking. It has also not been systematically defined which cellular sources of RANKL - arising from bone marrow mesenchymal lineage cells or hematopoietic lineage cells - play dominant roles in driving osteoclast activation. Clarifying these distinct forms and sources of RANKL will refine the conceptual framework of osteoclast regulation and provide a mechanistic basis for next-generation antiresorptive therapies that selectively target specific RANKL modalities to achieve more durable skeletal protection.

Keywords

Receptor activator of nuclear factor-κB ligand / bone marrow mesenchymal lineage cells / Hematopoietic stem cells / osteoclast / osteoprotegerin

References

[1] Wu Q,Wang C.Tetrahydroberberine prevents ovariectomy-induced bone loss by inhibiting RANKL-induced osteoclastogenesis and promoting osteoclast apoptosis.J Agric Food Chem2024;72:20383-95

[2] Kim AS,Castro-Martinez A.Temporal patterns of osteoclast formation and activity following withdrawal of RANKL inhibition.J Bone Miner Res2024;39:484-97 PMCID:PMC11262142

[3] Kumar S,Kim AS,McDonald MM.Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures.J Bone Miner Res2025;40:1017-34 PMCID:PMC12406127

[4] Anderson DM,Billingsley WL.A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.Nature1997;390:175-9

[5] Khosla S.Minireview: the OPG/RANKL/RANK system.Endocrinology2001 ;142:5050-5

[6] Boyce BF.Functions of RANKL/RANK/OPG in bone modeling and remodeling.Arch Biochem Biophys2008;473:139-46 PMCID:PMC2413418

[7] Lomaga MA,Sarosi I.TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling.Genes Dev1999;13:1015-24 PMCID:PMC316636

[8] Naito A,Tanaka S.Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice.Genes Cells1999;4:353-62

[9] Koga T,Inoue K.Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis.Nature2004;428:758-63

[10] Udagawa N,Nakamura M.Osteoclast differentiation by RANKL and OPG signaling pathways.J Bone Miner Metab2021;39:19-26

[11] Simonet WS,Dunstan CR.Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.Cell1997;89:309-19

[12] Rao S,Sigl V.RANKL and RANK: from mammalian physiology to cancer treatment.Trends Cell Biol2018;28:213-23

[13] Xiong J,Piemontese M.Soluble RANKL contributes to osteoclast formation in adult mice but not ovariectomy-induced bone loss.Nat Commun2018;9:2909 PMCID:PMC6060116

[14] Hikita A,Wakeyama H.Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kappaB ligand.J Biol Chem2006;281:36846-55

[15] Mizuno A,Hoshi M.Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis.J Bone Miner Metab2002;20:337-44

[16] Asano T,Nakai Y.Soluble RANKL is physiologically dispensable but accelerates tumour metastasis to bone.Nat Metab2019;1:868-75

[17] Xiong J,Jilka RL,Manolagas SC.Matrix-embedded cells control osteoclast formation.Nat Med2011;17:1235-41 PMCID:PMC3192296

[18] Xiong J.Osteocyte RANKL: new insights into the control of bone remodeling.J Bone Miner Res2012;27:499-505 PMCID:PMC3449092

[19] Kearns AE,Kostenuik PJ.Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.Endocr Rev2008;29:155-92 PMCID:PMC2528846

[20] Sims NA.Bone remodeling: multiple cellular interactions required for coupling of bone formation and resorption.Semin Cell Dev Biol2008;19:444-51

[21] O’Brien CA.Control of RANKL gene expression.Bone2010;46:911-9 PMCID:PMC2842447

[22] Suda T,Udagawa N,Gillespie MT.Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families.Endocr Rev1999;20:345-57

[23] Bord S,Beavan SR.The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts.Bone2003;32:136-41

[24] Galli C,Wang W.Commitment to the osteoblast lineage is not required for RANKL gene expression.J Biol Chem2009;284:12654-62

[25] Corral DA,Priemel M.Dissociation between bone resorption and bone formation in osteopenic transgenic mice.Proc Natl Acad Sci USA1998;95:13835-40 PMCID:PMC24916

[26] Zhang M,Bouxsein ML.Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization.J Biol Chem2002;277:44005-12

[27] Kobayashi T,Cobb BS.Dicer-dependent pathways regulate chondrocyte proliferation and differentiation.Proc Natl Acad Sci USA2008;105:1949-54 PMCID:PMC2538863

[28] Rodda SJ.Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors.Development2006;133:3231-44

[29] Usui M,Drissi H.Murine and chicken chondrocytes regulate osteoclastogenesis by producing RANKL in response to BMP2.J Bone Miner Res2008;23:314-25

[30] Masuyama R,Torrekens S.Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts.J Clin Invest2006;116:3150-9

[31] Gebhard S,Bauer E.Specific expression of Cre recombinase in hypertrophic cartilage under the control of a BAC-Col10a1 promoter.Matrix Biol2008;27:693-9 PMCID:PMC4013020

[32] Kalajzic I,Guo D.Dentin matrix protein 1 expression during osteoblastic differentiation, generation of an osteocyte GFP-transgene.Bone2004;35:74-82

[33] Yang W,Kalajzic I.Dentin matrix protein 1 gene cis-regulation: use in osteocytes to characterize local responses to mechanical loading in vitro and in vivo.J Biol Chem2005;280:20680-90

[34] Lu Y,Zhang S,Bonewald LF.DMP1-targeted Cre expression in odontoblasts and osteocytes.J Dent Res2007;86:320-5

[35] Kong YY,Sarosi I.OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis.Nature1999;397:315-23

[36] Zhou BO,Yue R.Bone marrow adipocytes promote the regeneration of stem cells and haematopoiesis by secreting SCF.Nat Cell Biol2017;19:891-903 PMCID:PMC5536858

[37] Zhou BO,Murphy MM,Morrison SJ.Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow.Cell Stem Cell2014;15:154-68 PMCID:PMC4127103

[38] Ambrosi TH,Graja A.Adipocyte accumulation in the bone marrow during obesity and aging impairs stem cell-based hematopoietic and bone regeneration.Cell Stem Cell2017;20:771-84.e6 PMCID:PMC5459794

[39] Hu Y,Zhi X.RANKL from bone marrow adipose lineage cells promotes osteoclast formation and bone loss.EMBO Rep2021;22:e52481 PMCID:PMC8406405

[40] Yu W,Yao L.Bone marrow adipogenic lineage precursors promote osteoclastogenesis in bone remodeling and pathologic bone loss.J Clin Invest2021;131:e140214

[41] Zhong L,Tower RJ.Single cell transcriptomics identifies a unique adipose lineage cell population that regulates bone marrow environment.Elife2020;9:e54695

[42] Lu J,Wang H.Bone marrow adipogenic lineage precursors are the major regulator of bone resorption in adult mice.Bone Res2025;13:39 PMCID:PMC11920254

[43] Walsh MC.Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond.Front Immunol2014;5:511 PMCID:PMC4202272

[44] Cawley KM,Guha AG.Local production of osteoprotegerin by osteoblasts suppresses bone resorption.Cell Rep2020;32:108052 PMCID:PMC7493998

[45] Weitzmann MN.The role of inflammatory cytokines, the RANKL/OPG axis, and the immunoskeletal interface in physiological bone turnover and osteoporosis.Scientifica2013;2013:125705 PMCID:PMC3820310

[46] Fischer V.Interaction between bone and immune cells: Implications for postmenopausal osteoporosis.Semin Cell Dev Biol2022;123:14-21

[47] Onal M,Chen X.Receptor activator of nuclear factor κB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss.J Biol Chem2012;287:29851-60

[48] Eghbali-fatourechi G,Sanyal A,Lacey DL.Role of RANK ligand in mediating increased bone resorption in early postmenopausal women.J Clin Investig2003;111:1221-30

[49] Xu J,Liu F,Deng Z.The effect of cytokines on osteoblasts and osteoclasts in bone remodeling in osteoporosis: a review.Front Immunol2023;14:1222129 PMCID:PMC10355373

[50] Wu D,Goering D,Veis D.Estrogen loss activates memory T-cells to compromise bone integrity through distinct cortical compartments in mice.J Bone Miner Res2025;40:1087-99 PMCID:PMC12475993

[51] Huang F,Li J.Osteoimmunology: the correlation between osteoclasts and the Th17/Treg balance in osteoporosis.J Cell Mol Med2022;26:3591-7 PMCID:PMC9258696

[52] Bhadricha H,Singh AK.Increased frequency of Th17 cells and IL-17 levels are associated with low bone mineral density in postmenopausal women.Sci Rep2021;11:16155 PMCID:PMC8352954

[53] Kittaka M,Levitan ME.Osteocyte RANKL drives bone resorption in mouse ligature-induced periodontitis.J Bone Miner Res2023;38:1521-40 PMCID:PMC11140853

[54] Crotti TN,Weedon H.Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis.Ann Rheum Dis2002;61:1047-54 PMCID:PMC1753975

[55] Ono T,Sasaki F.RANKL biology: bone metabolism, the immune system, and beyond.Inflamm Regen2020;40:2 PMCID:PMC7006158

[56] Weivoda MM.Macrophages and bone remodeling.J Bone Miner Res2023;38:359-69 PMCID:PMC10023335

[57] Clark D,Yang F.Age-related changes to macrophages are detrimental to fracture healing in mice.Aging Cell2020;19:e13112 PMCID:PMC7059136

[58] Zhang Y,Unger RE,Kirkpatrick CJ.Macrophage type modulates osteogenic differentiation of adipose tissue MSCs.Cell Tissue Res2017;369:273-86 PMCID:PMC5552848

[59] Söderström K,Colmenero P.Natural killer cells trigger osteoclastogenesis and bone destruction in arthritis.Proc Natl Acad Sci USA2010;107:13028-33 PMCID:PMC2919936

[60] Poubelle PE,Fernandes MJ,Marceau AA.Differential expression of RANK, RANK-L, and osteoprotegerin by synovial fluid neutrophils from patients with rheumatoid arthritis and by healthy human blood neutrophils.Arthritis Res Ther2007;9:R25 PMCID:PMC1906801

[61] Ando Y,Huynh NC.The neutrophil-osteogenic cell axis promotes bone destruction in periodontitis.Int J Oral Sci2024;16:18 PMCID:PMC10899642

[62] Schneider AH,Públio GA.Neutrophil extracellular traps mediate bone erosion in rheumatoid arthritis by enhancing RANKL-induced osteoclastogenesis.Br J Pharmacol2024;181:429-46

[63] Kim AR,Choi YH.The presence of neutrophils causes RANKL expression in periodontal tissue, giving rise to osteoclast formation.J Periodontal Res2020;55:868-76

[64] Walsh NC,Manning CA.Activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL.Genes Immun2013;14:336-45 PMCID:PMC3740552

[65] Kanzaki H,Suzuki M.Soluble RANKL cleaved from activated lymphocytes by TNF-α-converting enzyme contributes to osteoclastogenesis in periodontitis.J Immunol2016;197:3871-83 PMCID:PMC5120874

[66] Dickerson TJ,Stanecki C,Qui H.Rheumatoid and pyrophosphate arthritis synovial fibroblasts induce osteoclastogenesis independently of RANKL, TNF and IL-6.J Autoimmun2012;39:369-76 PMCID:PMC3593104

[67] Collin-Osdoby P,Anderson F,Maloney W.Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis.J Biol Chem2001;276:20659-72

[68] Kindle L,Kriss M,Collin-Osdoby P.Human microvascular endothelial cell activation by IL-1 and TNF-alpha stimulates the adhesion and transendothelial migration of circulating human CD14+ monocytes that develop with RANKL into functional osteoclasts.J Bone Miner Res2006;21:193-206

[69] Li Y,Greven J.Modulation of the hepatic RANK-RANKL-OPG axis by combined C5 and CD14 inhibition in a long-term polytrauma model.Front Immunol2024;15:1434274 PMCID:PMC11617561

[70] Moschen AR,Stadlmann S.The RANKL/OPG system and bone mineral density in patients with chronic liver disease.J Hepatol2005;43:973-83

[71] Monti F,Leoni L.RANK-RANKL-OPG axis in MASLD: current evidence linking bone and liver diseases and future perspectives.Int J Mol Sci.2024;25:9193 PMCID:PMC11395242

[72] Raje NS,Terpos E.Role of the RANK/RANKL pathway in multiple myeloma.Clin Cancer Res2019;25:12-20

[73] Buckle CH,Lawson MA.Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.PLoS ONE2012;7:e41127 PMCID:PMC3430669

[74] Chen G,Aprikian A,Goltzman D.Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation.Cancer2006;107:289-98

[75] Wu X,Dang L,Lu A.RANKL/RANK system-based mechanism for breast cancer bone metastasis and related therapeutic strategies.Front Cell Dev Biol2020;8:76 PMCID:PMC7026132

[76] Ohshiba T,Inada M.Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis.Br J Cancer2003;88:1318-26 PMCID:PMC2747560

[77] Honma M.[The potential of RANKL reverse signaling as a novel pharmacological target].Nihon Yakurigaku Zasshi2023;158:253-7

[78] Liang W,Li X.A RANKL-UCHL1-sCD13 negative feedback loop limits osteoclastogenesis in subchondral bone to prevent osteoarthritis progression.Nat Commun2024;15:8792 PMCID:PMC11466963